AR Scientific® is the branded marketing arm for URL Pharma and is currently marketing Qualaquin® and Bactrim™ (a trademark of Hoffman-La Roche, Inc.).
In the near term, Qualaquin® is expected to be the most significant revenue driver for the Company. AR Scientific® has an extensive NDA pipeline, with six mid to late stage products that are expected to launch over the next five years. Two NDA filings are expected in 2008 with the next branded product launch in 2009. Brand development activities target physicians, for unmet medical needs, or managed care organizations for commercial advantages, and are provided through our internal sales and marketing organization, partnerships, or licensing agreements.
For more information on Qualaquin®, click here.